Securities Fraud Class Action Filed Against Soleno Therapeutics, Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 14 2026
0mins
Should l Buy SLNO?
Source: Globenewswire
- Lawsuit Background: Soleno Therapeutics, Inc. (NASDAQ: SLNO) faces a securities fraud class action lawsuit for the period between March 26, 2025, and November 4, 2025, with investors having until May 5, 2026, to seek lead plaintiff status, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that Soleno made materially false statements regarding its DCCR drug's Phase 3 clinical trial, failing to disclose serious safety concerns, which could undermine investor confidence in the company's future prospects.
- Stock Price Impact: Following the financial results announcement on November 4, 2025, Soleno's stock price plummeted over 26% due to revelations of issues in the clinical trial, reflecting heightened market concerns about the company's viability.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for free legal consultations, highlighting the potential financial losses and risks associated with the ongoing litigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.690
Low
75.00
Averages
110.50
High
125.00
Current: 52.690
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soleno Therapeutics Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns regarding its DCCR drug during clinical trials, leading to investor losses when the true risks were revealed, indicating that the drug's commercial viability was severely underestimated.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked number one for securities class action settlements in 2017, showcasing its strong capabilities in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success to ensure optimal representation in the class action, avoiding those that merely act as intermediaries without actual litigation experience.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ: SLNO) is facing a securities class action lawsuit with a lead plaintiff deadline of May 5, 2026, urging those who purchased shares between March 26, 2025, and November 4, 2025, and suffered significant losses to submit their claims.
- Safety Risk Allegations: The lawsuit alleges that Soleno failed to disclose critical safety risks associated with its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, including severe side effects like fluid retention and potential heart failure in children.
- Data Integrity Issues: A report by activist short seller Scorpion Capital highlighted that Soleno's Phase 3 clinical trials relied on a controversial physician whose data showed irregularities, raising concerns about the drug's commercial viability and integrity.
- Stock Price Plunge: Following the November 4, 2025, announcement of Q3 financial results, which revealed disruptions in DCCR's launch trajectory, Soleno's stock plummeted 27% in a single day, indicating a severe loss of market confidence in the company's prospects.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. (NYSE: SILA) regarding its sale to Blue Owl Real Estate Capital LLC at $30.38 per share, as there may be violations of shareholder rights, aiming to ensure fair treatment for shareholders.
- Merger Scrutiny: The firm is also focusing on QXO, Inc. (NYSE: QXO) and its merger with TopBuild Corp., which could impact shareholder rights, and encourages QXO shareholders to understand their legal rights and options.
- Cash Acquisition Concerns: Soleno Therapeutics, Inc. (NASDAQ: SLNO) is being sold to Neurocrine Biosciences for $53.00 per share in cash, with potential adverse effects on shareholders, prompting Halper Sadeh LLC to seek increased compensation and additional disclosures for shareholders.
- Investor Protection Advocacy: Halper Sadeh LLC represents investors globally, committed to combating securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, highlighting its crucial role in protecting investor rights.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics for Securities Fraud
- Lawsuit Background: Kahn Swick & Foti has initiated a class action lawsuit against Soleno Therapeutics, alleging that the company failed to disclose critical information between March 26, 2025, and November 4, 2025, resulting in investor losses, highlighting significant transparency issues within the company.
- Allegation Details: The complaint asserts that Soleno and certain executives systematically minimized and failed to disclose substantial safety concerns related to the DCCR clinical trial, including excessive fluid retention among participants, indicating serious safety risks that could impact the product's market performance.
- Business Impact: The undisclosed safety risks raise doubts about DCCR's commercial viability, potentially leading to increased patient discontinuation rates, reduced prescriber willingness, and adverse regulatory actions, which could further damage the company's reputation and expose it to legal liabilities.
- Investor Action: Affected investors must request to be appointed as lead plaintiffs by May 5, 2026, to seek recovery in the lawsuit, demonstrating active engagement from investors regarding corporate governance and accountability in the wake of alleged fraud.
See More
Reminder of Class Action Lawsuit for Soleno Therapeutics Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics securities between March 26, 2025, and November 4, 2025, to apply as lead plaintiffs by May 5, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety issues related to its DCCR drug during clinical trials, including serious side effects like fluid retention in participants, exposing investors to greater financial risks.
- Legal Counsel Advice: Rosen Law Firm emphasizes the importance of selecting experienced legal counsel to effectively protect investors' rights, advising against working with firms that merely act as intermediaries.
- Historical Performance: The firm has recovered over $438 million for investors in 2019 alone and achieved the largest securities class action settlement against a Chinese company in 2017, showcasing its strong capabilities in securities litigation.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Reminder: Hagens Berman law firm alerts investors of the upcoming lead plaintiff deadline on May 5, 2026, for the securities class action against Soleno Therapeutics (NASDAQ:SLNO), urging those who purchased shares between March 26, 2025, and November 4, 2025, and suffered significant losses to submit their claims.
- Safety Risk Allegations: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, concealing critical safety risks that have severely undermined investor confidence in the company’s future.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 financial results, admitting disruptions in DCCR's launch trajectory, which led to a staggering 27% drop in stock price in a single day, reflecting market disappointment in the company's prospects.
- Whistleblower Program: Hagens Berman encourages whistleblowers with non-public information to assist in the investigation, as under the new program, those providing original information may receive rewards of up to 30% of any successful SEC recovery, further driving the inquiry into Soleno's practices.
See More
Soleno Therapeutics Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics (NASDAQ:SLNO) common stock between March 26, 2025, and November 4, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety concerns regarding its DCCR drug during clinical trials, leading to investor losses when the true risks were revealed, indicating that the drug's commercial viability was severely underestimated.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked number one for securities class action settlements in 2017, showcasing its strong capabilities in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success to ensure optimal representation in the class action, avoiding those that merely act as intermediaries without actual litigation experience.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Background: Hagens Berman reminds investors that Soleno Therapeutics (NASDAQ: SLNO) is facing a securities class action lawsuit with a lead plaintiff deadline of May 5, 2026, urging those who purchased shares between March 26, 2025, and November 4, 2025, and suffered significant losses to submit their claims.
- Safety Risk Allegations: The lawsuit alleges that Soleno failed to disclose critical safety risks associated with its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, including severe side effects like fluid retention and potential heart failure in children.
- Data Integrity Issues: A report by activist short seller Scorpion Capital highlighted that Soleno's Phase 3 clinical trials relied on a controversial physician whose data showed irregularities, raising concerns about the drug's commercial viability and integrity.
- Stock Price Plunge: Following the November 4, 2025, announcement of Q3 financial results, which revealed disruptions in DCCR's launch trajectory, Soleno's stock plummeted 27% in a single day, indicating a severe loss of market confidence in the company's prospects.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. (NYSE: SILA) regarding its sale to Blue Owl Real Estate Capital LLC at $30.38 per share, as there may be violations of shareholder rights, aiming to ensure fair treatment for shareholders.
- Merger Scrutiny: The firm is also focusing on QXO, Inc. (NYSE: QXO) and its merger with TopBuild Corp., which could impact shareholder rights, and encourages QXO shareholders to understand their legal rights and options.
- Cash Acquisition Concerns: Soleno Therapeutics, Inc. (NASDAQ: SLNO) is being sold to Neurocrine Biosciences for $53.00 per share in cash, with potential adverse effects on shareholders, prompting Halper Sadeh LLC to seek increased compensation and additional disclosures for shareholders.
- Investor Protection Advocacy: Halper Sadeh LLC represents investors globally, committed to combating securities fraud and corporate misconduct, having successfully recovered millions for defrauded investors, highlighting its crucial role in protecting investor rights.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics for Securities Fraud
- Lawsuit Background: Kahn Swick & Foti has initiated a class action lawsuit against Soleno Therapeutics, alleging that the company failed to disclose critical information between March 26, 2025, and November 4, 2025, resulting in investor losses, highlighting significant transparency issues within the company.
- Allegation Details: The complaint asserts that Soleno and certain executives systematically minimized and failed to disclose substantial safety concerns related to the DCCR clinical trial, including excessive fluid retention among participants, indicating serious safety risks that could impact the product's market performance.
- Business Impact: The undisclosed safety risks raise doubts about DCCR's commercial viability, potentially leading to increased patient discontinuation rates, reduced prescriber willingness, and adverse regulatory actions, which could further damage the company's reputation and expose it to legal liabilities.
- Investor Action: Affected investors must request to be appointed as lead plaintiffs by May 5, 2026, to seek recovery in the lawsuit, demonstrating active engagement from investors regarding corporate governance and accountability in the wake of alleged fraud.
See More
Reminder of Class Action Lawsuit for Soleno Therapeutics Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Soleno Therapeutics securities between March 26, 2025, and November 4, 2025, to apply as lead plaintiffs by May 5, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Soleno concealed significant safety issues related to its DCCR drug during clinical trials, including serious side effects like fluid retention in participants, exposing investors to greater financial risks.
- Legal Counsel Advice: Rosen Law Firm emphasizes the importance of selecting experienced legal counsel to effectively protect investors' rights, advising against working with firms that merely act as intermediaries.
- Historical Performance: The firm has recovered over $438 million for investors in 2019 alone and achieved the largest securities class action settlement against a Chinese company in 2017, showcasing its strong capabilities in securities litigation.
See More
Soleno Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Reminder: Hagens Berman law firm alerts investors of the upcoming lead plaintiff deadline on May 5, 2026, for the securities class action against Soleno Therapeutics (NASDAQ:SLNO), urging those who purchased shares between March 26, 2025, and November 4, 2025, and suffered significant losses to submit their claims.
- Safety Risk Allegations: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, concealing critical safety risks that have severely undermined investor confidence in the company’s future.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 financial results, admitting disruptions in DCCR's launch trajectory, which led to a staggering 27% drop in stock price in a single day, reflecting market disappointment in the company's prospects.
- Whistleblower Program: Hagens Berman encourages whistleblowers with non-public information to assist in the investigation, as under the new program, those providing original information may receive rewards of up to 30% of any successful SEC recovery, further driving the inquiry into Soleno's practices.
See More
